Rapid case ascertainment (case identification within two months after diagnosis) is critical to the successful conduct of quality, population-based, epidemiologic studies, particularly case-control studies that incorporate molecular biology and biomarkers. The goal of the Rapid Case Ascertainment (RCA) Core, under the direction of Dr. Andrew Olshan, is to support population-based epidemiology research by providing personnel for the rapid ascertainment of cancer cases in North Carolina. The RCA Core works with the NC Central Cancer Registry and investigators to facilitate case identification and data collection including traveling to and working with smaller, undermanned hospitals, located primarily in rural central and eastern North Carolina counties. The RCA Core also provides consultation and administrative assistance to researchers through the coordination of project IRB approvals and HIPAA compliance at participating hospitals; reports to hospitals and tumor registrars; database development; and activities among project investigators, the NC Central Cancer Registry, and related state committees. This Core Facility makes possible continued quality, cost-effective population-based research in diverse communities. The four current circuit-riding data coordination positions have helped reduce the workload from ongoing studies by providing centralized coordination ascertainment, especially for hospitals in rural and underserved counties. Case-finding takes place for multiple studies during a single trip, providing a high degree of efficiency and cost effectiveness for the studies. In 2003, six peer-reviewed members from two programs used the Core to identify 9,256 new cases new cases of breast, colorectal, prostate, head and neck, and ovarian cancer cases in selected counties for eight studies. UNC Lineberger investigators continue to expand their efforts in population-based studies that rely on rapid case ascertainment. Future plans include the development of a secure website dedicated to RCA in North Carolina. This will be a useful tool to provide valuable information to hospital cancer registrars and investigators for ongoing and upcoming research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-30
Application #
7100756
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-12-01
Project End
2009-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
30
Fiscal Year
2005
Total Cost
$72,086
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Zuze, Takondwa; Painschab, Matthew S; Seguin, Ryan et al. (2018) Plasmablastic lymphoma in Malawi. Infect Agent Cancer 13:22
Wang, Jeremy R; Holt, James; McMillan, Leonard et al. (2018) FMLRC: Hybrid long read error correction using an FM-index. BMC Bioinformatics 19:50
Lee, Janie M; Abraham, Linn; Lam, Diana L et al. (2018) Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography. J Clin Oncol 36:2070-2077
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Shao, Wenwei; Chen, Xiaojing; Samulski, Richard J et al. (2018) Inhibition of antigen presentation during AAV gene therapy using virus peptides. Hum Mol Genet 27:601-613
Gao, Yanzhe; Kardos, Jordan; Yang, Yang et al. (2018) The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Sci Rep 8:15304
Schaefer, Kristina N; Bonello, Teresa T; Zhang, Shiping et al. (2018) Supramolecular assembly of the beta-catenin destruction complex and the effect of Wnt signaling on its localization, molecular size, and activity in vivo. PLoS Genet 14:e1007339
Bonacci, Thomas; Suzuki, Aussie; Grant, Gavin D et al. (2018) Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/C substrates. EMBO J 37:
Zhang, Zhi-Min; Lu, Rui; Wang, Pengcheng et al. (2018) Structural basis for DNMT3A-mediated de novo DNA methylation. Nature 554:387-391
Desai, Neelam V; Torous, Vanda; Parker, Joel et al. (2018) Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay. Breast Cancer Res 20:75

Showing the most recent 10 out of 1525 publications